NEW YORK (GenomeWeb News) – Real Time Genomics and Knome today announced a deal to integrate the Real Time Genomics Variant platform into every shipment of the knoSys 100 interpretation system.
The deal allows Knome customers to buy the RTG platform directly from Knome sales representatives and allows them to acquire the RTG analytics engine as an upgrade to the system, the two firms said.
Knome CEO Wolfgang Daum noted that demand for genome interpretation tools has "surged" as translational researchers and clinicians use next-generation sequencing in their work. "Concomitant with that demand is the need for accurate and easy-to-use industrial grade analysis that meets expectations of clinical accuracy," he said.
Financial and other terms of the deal were not disclosed.
The deal is the third in recent weeks for Real Time Genomics, following an announcement last week with the J. Craig Venter Institute, focused on genetic mutations that induce pluripotent stem cells acquire during differentiation, and an announcement in April with Omicia to integrate each other's platforms into a workflow for identifying disease-causing variants for the interpretation of childhood diseases.